Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aeruginosa in sub-Saharan Africa: A systematic review and meta-analysis

Background: Carbapenems are drugs of last resort and resistance to them is considered a great public health threat, especially in notorious nosocomial pathogens like Acinetobacter baumannii and Pseudomonas aeruginosa. In this study, we aimed to determine the prevalence of carbapenem resistance in A. baumannii and P. aeruginosa infections in Sub Saharan Africa. Methods: Databases (PubMed, Scopus, Web of Science, and African Journal Online) were systematically searched following the Preferred Reporting Items for Systematic review and meta analysis protocols (PRISMA-P) 2020 statements for articles reporting carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) prevalence between 2012 and 2022. Pooled prevalence was determined with the random effect model in R. Results: A total of 47 articles were scanned for eligibility, among which 25 (14 for carbapenem-resistant A. baumanii and 11 for carbapenem-resistant P. aeruginosa) were included in the study after fulfilling the eligibility criteria. The pooled prevalence of CRPA in the present study was estimated at 8% (95% CI; 0.02 to 0.17; I2=98%; P <0.01). There was high heterogeneity (Q=591.71, I2=98.9%; P<0.0001). The pooled prevalence of CRAB in the present study was estimated at 20% (95% CI; 0.04 to 0.43; I2=99%; P <0.01). There was high heterogeneity (Q=1452.57, I2=99%; P<0.0001). Carbapenem-resistant A. baumannii prevalence based on sample source gave estimates of 24% (95% CI; 6 to 49; I2=99%; P<0.01). The carbapenamse genes commonly isolated from A. baumanii in this study include blaOXA23, blaOXA48, blaGES., blaNDM, blaVIM, , blaOXA24, blaOXA58, blaOXA51, blaSIM-1, blaOXA40, blaOXA66, blaOXA69, blaOXA91, with blaOXA23 and blaVIM being the most common. On the other hand, blaNDM, blaVIM, blaIMP,, blaOXA48, blaOXA51, blaSIM-1, blaOXA181, blaKPC, blaOXA23, blaOXA50 were the commonly isolated carbapenemase genes in P. aeruginosa, among which blaVIM and blaNDM genes were the most frequently isolated. Conclusion: Surveillance of drug-resistant pathogens in sub-Saharan Africa is essential in reducing the disease burden in the region and this study has shown that the region has significantly high multidrug resistant pathogen prevalence. This is a wakeup call for policymakers to put in place measures to reduce the spread of these critical priority pathogens.

[1]  Alan D. Lopez,et al.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.

[2]  K. Hardie,et al.  JMM Profile: Carbapenems: a broad-spectrum antibiotic , 2021, Journal of medical microbiology.

[3]  A. Zerbo,et al.  Water sanitation and hygiene in Sub-Saharan Africa: Coverage, risks of diarrheal diseases, and urbanization , 2021 .

[4]  Yan Liu,et al.  Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing Pseudomonas aeruginosa , 2021, Antibiotics.

[5]  Dan Yang,et al.  Rapid Broad Spectrum Detection of Carbapenemases with a Dual Fluorogenic-Colorimetric Probe. , 2021, Journal of the American Chemical Society.

[6]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[7]  S. Songca,et al.  Prevalence and molecular analysis of multidrug-resistant Acinetobacter baumannii in the extra-hospital environment in Mthatha, South Africa , 2019, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[8]  A. Whiteside,et al.  New and Re-Emerging Infectious Diseases in Sub-Saharan Africa , 2017, Africa's Population: In Search of a Demographic Dividend.

[9]  J. O'Neill,et al.  Tackling drug-resistant infections globally: final report and recommendations , 2016 .

[10]  Y. Carmeli,et al.  The negative impact of antibiotic resistance. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  G. Meletis,et al.  Carbapenem resistance: overview of the problem and future perspectives , 2016, Therapeutic advances in infectious disease.

[12]  A. Pantosti,et al.  Antimicrobial resistance: a global multifaceted phenomenon , 2015, Pathogens and global health.

[13]  S. Amyes,et al.  OXA β-Lactamases , 2014, Clinical Microbiology Reviews.

[14]  G. B. Golding,et al.  Antibiotic resistance is ancient , 2011, Nature.

[15]  Damià Barceló,et al.  Multi-residue analytical methods using LC-tandem MS for the determination of pharmaceuticals in environmental and wastewater samples: a review , 2006, Analytical and bioanalytical chemistry.

[16]  L. Mandell,et al.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. , 1998, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.